Bayesian borrowing

R&D

Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.